Better patient outcomes driven by data: Value-based Healthcare in Canada
In the 2023 report Taking Back Health Care from The Public Policy Forum, the authors call on leaders to “act collaboratively to realize a modern, health data ecosystem for Canada.” Similarly, The Canadian Institutes of Health Research identifies inter-organization data gathering and sharing as a key gap within Canada’s health care system.
The federal agency’s 2021-26 Strategic Plan stresses the need to “create opportunities for researchers, care providers, decision makers, and patients to work together in the digital health space to improve their understanding and use of data.” While the report points to gaps and challenges, such as siloed data across our health care system, it also shares examples of excellence and innovation where “delivery systems are using data to continuously learn, adapt and improve.”
At J&J MedTech Canada, we’re committed to offering capabilities in technological advancement, evidence generation, and digital solutions that optimize the care pathway and system efficiency with real-time data. Johnson amp; Johnson’s century-long history has proven that “technological innovations” have always been at the heart of better care solutions, and we are doing everything we can to accelerate the adoption of value-based healthcare (VBHC) models in Canada and around the world.
As an industry partner, we believe it is essential these models are available to providers and patients and are procured based on added value—assessed and validated by real-world data and evidence—across the full spectrum of care pathways. To that end, we have embarked upon a strategic long-term initiative known as “P-Value.” As the name of the initiative suggests, we aim to demonstrate our position as a health system solution partner to Providers, Payers, Policymakers, Procurement bodies, and most importantly, Patients at the centre.
P-Value aims to define and deliver value that matters to different healthcare stakeholders and support the shift in procurement environment towards better health outcomes for the patients, economic outcomes for the healthcare system, and overall better experience for patients and providers. At J&J MedTech Canada, we approach this goal through a Quintuple Aim approach that builds on evidence, patient and system needs, and policy advocacy efforts.
Quintuple Aim is a health care concept based on improved patient experience with better outcomes and efficient delivery of care, but that also values clinician well-being and social health equity. This lens can bring a whole new level of depth to our understanding of patient-centered care. We believe it is imperative that our innovative products, solutions and services are available to providers and patients, and are procured based on added value across the full spectrum of care pathway.
Today, we are pursuing this approach, that best aligns to providing access to timely and quality care, in three priority areas: ablation for atrial fibrillation, hip and knee replacements, and c-sections. We’ve also been working with leading hospitals to validate select innovations designed to help reduce surgical infections, shorten surgery and enable faster recovery after procedures such as knee replacement.
Most promising with these nascent partnerships is the willingness to take a broader view of where value lands in the patient journey. Rather than narrowly focus on cost in the operating room, value in terms of readmissions to hospital, revision surgeries and overall hospital efficiency are all being assessed and valued as part of the intervention.
We recognize VBHC puts additional financial risk on industry, particularly when linked to outcomes-based or risk-share agreements. But this risk is appropriate if it leads to a partnership between industry and health care partners/providers that enables co-creation of evidence that demonstrates value.
We are committed to engaging with payers, providers, policymakers, and other stakeholders to co-create flexible, local solutions that enable sustained, affordable access to transformational devices, technologies, and services while delivering better outcomes for patient populations. It’s why we continue to explore new initiatives with like-minded partners and hospitals to generate real-world data and evidence.
As we continue our dialogue around using VBHC as a more intensive procurement tool, it should be noted that this practice may not apply to all technologies or solutions at play in Canada’s health care system. Traditional procurement practices may be a more efficient way to approach purchasing in commoditized areas, or with lower value products that are undifferentiated in the market.
Rather, VBHC should be reserved for unique solutions that are posited to add real value to the patient and/or health system across boundaries. After all, Canadian patients can not afford to wait any longer and time is of the essence for this shift. Now is the time to start realizing the benefits of VBHC.
Over the past year, I’ve written about everything our healthcare system is up against here in Canada, so I would be remiss if I didn’t take this opportunity to share my immense gratitude for all those who continue to care for Canadians despite these challenges. Thanks for all that you do.
Chief Commercial Officer I CCO I UBC I Driving Revenue Growth Through Creative Strategy & Effective Tactical Execution | Building High Performing Teams & Winning Cultures | Leading Healthcare Tech Pharmaceutical Services
9 个月We're seeing important movement towards #RWE in US healthcare, as well, not just when exploring value-based care but also in drug development. This strategy shift is crucial for improved data collection and actionable insights. Great piece!